Valuation: Candel Therapeutics, Inc.

Market Cap 783M 678M 635M 579M 1.09B 74.64B 1.11B 7.47B 2.92B 37.37B 2.94B 2.87B 125B P/E 2026 *
-11.8x
P/E 2027 * -15x
Enterprise Value 783M 678M 635M 579M 1.09B 74.64B 1.11B 7.47B 2.92B 37.37B 2.94B 2.87B 125B EV / Sales 2026 *
-
EV / Sales 2027 * 18.3x
Free-Float
84.33%
Yield 2026 *
-
Yield 2027 * -
07-13 Stifel Nicolaus Initiates Coverage on Candel Therapeutics With Buy Rating, $22 Price Target MT
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-22 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-21 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 54,895,849 Common Stock of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-15 Candel Therapeutics reports extended clinical benefit over multiple clinical endpoints in patients from phase 3 trial of aglatimagene besadenovec (CAN-2409) RE
05-15 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (CAN-2409) In Localized Prostate Cancer Under Prolonged Follow-Up At AUA 2026 Annual Meeting CI
05-15 Candel Therapeutics, Inc. - Special Call
05-14 Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI

Last Transcript: Candel Therapeutics, Inc.

1 day+0.28%
1 week+2.10%
Current month+6.69%
1 month+12.54%
3 months+22.48%
6 months+90.71%
Current year+89.03%
1 week 10.35
Extreme 10.35
10.9
1 month 9.16
Extreme 9.1612
10.9
Current year 4.44
Extreme 4.44
11.36
1 year 4.35
Extreme 4.35
11.36
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.78
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap.
7/6/26 A Free

Executive/Senior Manager

285,000 0.3890%
6/30/26 A Free

Director

381 0.0005%
6/30/26 A Free

Director

1,331 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%+2.10%+68.19%+828.70% 783M
+0.81%+0.86%+3.70%+14.41% 48.72B
-0.14%+4.03%+482.13%+584.43% 43.99B
-0.06%+9.62%+24.63%+81.63% 40.82B
-0.87%+2.40%+30.01%+9.95% 39.79B
-4.04%+6.15%+23.03%+48.00% 32.7B
-1.41%+1.57%+29.98%+123.68% 16.66B
+0.35%+4.61% - - 16.84B
+0.46%+0.06%+4.67%+21.26% 13.95B
+0.84%+9.07%+86.17%+32.60% 13.58B
Average -0.38%+3.77%+83.61%+193.85% 26.78B
Weighted average by Cap. -0.51%+3.93%+104.12%+140.09%

Financials

2026 *2027 *
Net sales - 42.84M 37.11M 34.77M 31.72M 59.63M 4.09B 60.54M 409M 160M 2.05B 161M 157M 6.82B
Net income -61.55M -53.32M -49.96M -45.57M -85.67M -5.87B -86.99M -588M -230M -2.94B -231M -226M -9.8B -54.13M -46.89M -43.94M -40.08M -75.34M -5.16B -76.5M -517M -202M -2.58B -203M -199M -8.62B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
12/08/26 $10.68 +0.28% 1,378,941
11/08/26 $10.65 +1.43% 857,172
10/08/26 $10.50 -0.85% 648,486
07/08/26 $10.59 +0.09% 800,789
06/08/26 $10.58 +1.15% 1,298,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.68USD
Average target price
20.50USD
Spread / Average Target
+91.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock